Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
The DOI matches its Crossref record; 73 of the 78 references it cites were found in a registry or an index.
Abstract
The availability of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as liraglutide and semaglutide, and a GLP-1 and glucose dependent insulinotropic polypeptide coagonist (tirzepatide) represents a paradigm shift in the management of both type 2 diabetes and obesity. There is now considerable attention, including in the public media, on the effect of both long-acting and short-acting GLP-1RAs to delay gastric emptying. Although slowed gastric emptying is integral to reducing post-prandial blood glucose responses in type 2 diabetes, marked slowing of gastric emptying might also increase the propensity for longer intragastric retention of food, with a consequent increased risk of aspiration at the time of surgery or upper gastrointestinal endoscopy. This Personal View summarises current knowledge of the effects of GLP-1 and GLP-1RAs on gastrointestinal physiology, particularly gastric emptying, and discusses the implications for the development of sound pre-operative or pre-procedural guidelines. The development of pre-procedural guidelines is currently compromised by the poor evidence base, particularly in relation to the effect of long-acting GLP-1RAs on gastric emptying. We suggest pre-procedural management pathways for individuals on GLP-1RA-based therapy and discuss priorities for future research.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“concerns have been raised about the risks associated with requiring an extended period of withdrawal, which may result in worsening glycaemic control among patients managing type 2 diabetes [18, 21, 24, 25].”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [24]
In the citing paper
“They cause a glucose‐dependent increase in insulin secretion from beta cells but have multiple other effects, including alteration of glucagon secretion from alpha cells: GLP‐1 reducing glucagon secretion, with GIP increasing it; and delaying gastric emptying, thus slowing the rise in postprandial glucose [8, 26, 27].”
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
The mechanism of pancreatic secretion
Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,269
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
Gastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus
Horowitz, M., Harding, P. E., Maddox, A. F., Wishart, J. M., Akkermans, L. M. A., Chatterton, B. E., & Shearman, D. J. C. (1989) · Diabetologia · doi:10.1007/bf00265086 · Cited by 392
Self-citationRelation between antral motility and gastric emptying of solids and liquids in humans
Camilleri, M., Malagelada, J. R., Brown, M. L., Becker, G., & Zinsmeister, A. R. (1985) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1985.249.5.g580 · Cited by 362
Self-citationRelationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus
Horowitz, M., Maddox, A., Wishart, J., Harding, P., Chatterton, B., & Shearman, D. C. (1991) · European Journal of Nuclear Medicine · doi:10.1007/bf00186645 · Cited by 326
Self-citation
Cited by
El‐Boghdadly, K., Dhesi, J., Fabb, P., Levy, N., Lobo, D. N., McKechnie, A., Mustafa, O., Newland‐Jones, P., Patel, A., Pournaras, D. J., et al. (2025) · Anaesthesia · doi:10.1111/anae.16541 · Cited by 147
“Due to evidence of delayed gastric emptying [5 – 8], along with published reports of regurgitation and pulmonary aspiration [9 – 12], con fl icting suggestions have been made for peri-operative management of patients taking GLP-1RAs [13 – 16].”
Castrillon, J., Rele, S., Sumithran, P., Hii, M., Thuraisingam, S., Spelman, T., Phan, T., Choong, P., Dowsey, M., & Shadbolt, C. (2025) · Anaesthesia · doi:10.1111/anae.16601 · Cited by 65
Fan, Y., Liu, Y., Shao, C., Jiang, C., Wu, L., Xiao, J., & Tang, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125486 · Cited by 62
“This receptor and its agonists show important therapeutic potential for the treatment of metabolic diseases [48–50].”
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 40
“They are reduced by delaying dose titration and account for discontinuation in 5 % of patients in most of the recent clinical trials [115].”
Gupta, O., Pradhan, T., & Chawla, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118264 · Cited by 33
Metadata
- Authors
- Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M.
- Affiliations
- The University of Adelaide (AU)
- Haukeland University Hospital (NO)
- Mayo Clinic (US)
- Corresponding author
- Horowitz, Michael
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2024-10
- Volume
- 9
- Issue
- 10
- Pages
- 957-964
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W4401230453
- Cited by
- 144
- References
- 78
- Citations by year
- 2026: 68 · 2025: 67 · 2024: 9
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- GLP-1 receptor agonists, gastric emptying, aspiration risk, liraglutide, semaglutide, tirzepatide, upper gastrointestinal endoscopy, type 2 diabetes, obesity, postprandial blood glucose
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Gastric Emptying, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. https://app.cochat.ai/papers/10.1016/s2468-1253(24)00188-2
- The paper
- Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024). Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(24)00188-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.